Participate in a Brain Cancer Clinical Trial

Now Recruiting Patients with Recurrent Glioblastoma (GBM)


Trial Information

Plus Therapeutics is developing a new targeted radiation therapy, REYOBIQ™ (rhenium Re186 obisbemeda), for central nervous system cancers such as Recurrent Glioblastoma. This clinical trial is for cancer patients with a glioma (type of brain tumor) that has come back after standard treatment options like surgery, radiation, or chemotherapy.

This FDA-approved Phase 2 clinical trial can enroll up to 30-40 patients and is a prospective, multicenter, and open-label trial. In this trial, the study doctor will give Recurrent Glioblastoma patients a single dose of REYOBIQ™ (rhenium Re186 obisbemeda), a specially designed radioactive drug.

ReSPECT-GBM is supported by the U.S. National Institutes of Health / National Cancer Institute.

View Trial on ClinicalTrials.gov

View ReSPECT-GBM Clinical Trial Guide for Patients

NATIONAL TRIAL REFERENCE NUMBER

NCT01906385

When speaking with your physician, please have the national trial reference number available.

46

Patients Treated to Date 

View our ReSPECT-GBM Trial Quick Overview

Single Group

  • All patients who enroll in the trial will receive REYOBIQ™ (rhenium Re186 obisbemeda)  while on the study.

Phase 2

  • Phase 2:  If a new medication is found to be reasonably safe in a Phase 1 study, it can then be evaluated in a Phase 2 study to determine if it works.  Doctors will assess whether the new medication provides a specific benefit or response, such as tumor shrinkage, improved quality of life, or longer patient survival.

Progress

  • Actual Study Start:  June 3, 2015
  • Estimated Phase Completion:  December 2025 (the date that the last participant in a clinical study is examined or receives an intervention and that data for the primary outcome measure are collected)

Plus Therapeutics is evaluating REYOBIQ™ (rhenium Re186 obisbemeda) , a novel radiotherapy for brain cancer patients, in the U.S. NIH-supported ReSPECT-GBM Phase 2 clinical trial.

Watch now to learn more.

Patient Eligibility

Only a qualified healthcare professional can determine whether or not you are eligible to participate in a clinical trial. However, this information may be beneficial in initiating a conversation with your physician. Patient reimbursement of up to $599 for time and travel is available. Healthy volunteers are not needed.

Condition

Recurrent Glioblastoma

age-range

Age Range

Adults, 18 Years and Older

gender

Gender

All

Imaging

Able to undergo a MRI scan

Prior Medication

Have not taken Avastin (bevacizumab)

Principal Investigators

There is a physician who is responsible for the scientific and technical direction of the clinical trial at each location.

Andrew Brenner, M.D., Ph.D.

UT Health San Antonio
Mays Cancer Center
About Dr. Brenner

Pierre Giglio, M.D.

The Ohio State University Cancer Center
Columbus, Ohio
About Dr. Giglio

Toral Patel, M.D.

UT Southwestern Medical Center
Peter O’Donnell Jr. Brain Institute
About Dr. Patel

Michael Schulder, M.D.

North Shore University Hospital
New York
About Dr. Schulder

Trial Locations

There are currently 3 clinical trial locations in the United States that are actively screening and enrolling patients.

Please visit this website regularly for updates as new locations are added.

UT Health

San Antonio, Texas

Ohio State University

Columbus

UT Southwestern

Dallas, Texas

North Shore University Hospital

Manhasset, NY

What Can You Do Next?

Participating in a clinical trial is an important decision. If you believe this clinical trial might be a good fit and are interested in participating, please take the next step to see if you are eligible.

Discuss With Your Physician

Anyone participating in a clinical trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll.  If you are interested in participating in a clinical trial, please talk to your physician first.

Print Friendly, PDF & Email

Print, save, or email this page to your physician to discuss at your next visit.

Be sure to have National Trial Reference Number NCT01906385 available.

View the ReSPECT-GBM Clinical Trial Guide PDF

Contact A Trial Coordinator

A trial coordinator is a specialized researcher who supports the management and coordination of clinical research studies.  If you are interested in participating in a clinical trial, you may call a trial coordinator directly at one of the trial locations below.

UT Health

San Antonio, Texas

Leticia Velten
210-450-1921
velten@uthscsa.edu

Ohio State University Cancer Center

Columbus

Jake Lanning
614-685-2435
jake.lanning@osumc.edu

UT Southwestern

Dallas, Texas

  Briana Carter
  214-645-2148
  Briana.carter@UTSouthwestern.edu

North Shore University Hospital

Manhasset, NY

  Mark Amandola
  516-424-7266
  mamandola@northwell.edu

Contact Us

Request More Information

Emails

14 + 6 =

News

Publications

Abstracts

Brenner, Andrew et al.  “Safety and Feasibility of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma:  The ReSPECT Phase 1 Trial.”  Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Pages vi65-vi66.

Brenner, Andrew et al.  “High Absorbed Doses of Rhenium-186 NanoLiposomes (RNL) in Recurrent GBM:  A Phase 1 Study.”  Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii186.

Posters

Brenner, Andrew et al. “Update Report of the ReSPECT Trials: Treatment of Recurrent Glioblastoma and Leptomeningeal Metastases with Rhenium (186Re) Obisbemeda.” NMN Precision Medicine Symposium 2024. 

Brenner, Andrew et al. “Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal Metastases Phase 1 Dose Escalation Trial: Update of Initial Safety and Feasibility.” NCCN Annual 2024. 

Brenner, Andrew et al. “Rhenium (186Re) Obisbemeda (186RNL) in Recurrent Glioblastoma via Convection Enhanced Delivery: A Report on Phase 2.” SNO Annual Meeting 2023.

Brenner, Andrew et al. “Update Report of the ReSPECT-GBM Phase 1 Dose Escalation Trial of Rhenium (186Re) Obisbemeda (186RNL) in Recurrent Glioma via Convection Enhanced Delivery.” SNO Annual Meeting 2023.

Brenner, Andrew et al. “Safety and Feasibility Results from a Phase 1/2 Clinical Trial of Rhenium (186Re) Obisbemeda (186RNL) in Recurrent Glioma: The ReSPECT-GBM Trial.” SNO/ASCO CNS Cancer Conference 2023.

LaFrance, Norman et al.  “Safety and Feasibility of (186Re) Obisbemeda (Rhenium-186 Nanoliposome, 186RNL) in Recurrent Glioma: The ReSPECTTM-GBM Phase 1/2 Trial.”  SNMMI 2023 Annual Meeting.

Brenner, Andrew et al.  “Safety & Feasibility of Rhenium-186 Nanoliposomes (186RNL) in Recurrent Glioma: the ReSPECT Phase 1 Trial.”  2022 Annual Conference on CNS Clinical Trials & Brain Metastases.

Floyd, John et al.  “Image-Guided Rhenium-186 NanoLiposome (186RNL) Brachytherapy in the Treatment of Recurrent Glioblastoma:  Technique, Image Analysis, Dosimetry, and Monitoring.”  2021 ASTRO Annual Meeting.

Brenner, Andrew et al.  “Safety and Feasibility of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma:  the ReSPECT Phase 1 Trial.”  E-Poster, 2021 American Society of Clinical Oncology Annual Meeting, June 4-8, 2021.

Brenner, Andrew et al.  “Safety and Feasibility of Rhenium-186 NanoLiposomes (RNL) in Recurrent GBM:  the ReSPECT Phase 1 Trial.”  E-Poster, 2020 Society for Neuro-Oncology Annual Meeting, November 19-21, 2020.

Presentations

Treatment of Recurrent Glioblastoma via Convection Enhanced Delivery with Rhenium (186Re) Obisbemeda: ReSPECT-GBM Phase 1/2 Trial Update, Congress of Neurological Surgeons Annual Meeting 2024, September 30, 2024

Targeted Radiolabeled Nanoliposomes for Rare CNS Cancers: An Update on the ReSPECT Phase 1/2 Trials, Gordon Research Conference, July 8, 2024

KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference, SNO Annual Meeting 2023, November 20, 2023.

ReSPECT-GBM Clinical Trial Update, SNMMI 2023 Annual Meeting, June 26, 2023

Safety and Feasibility of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma: the ReSPECT™ Phase 1/2a Trial, EANM Congress, October 19, 2022

Resources

Updates

REYOBIQ™: The Future of CNS Cancer Care

REYOBIQ™: A Promising Radiotherapeutic Advancing Treatment for Glioblastoma, Leptomeningeal Metastases, and Pediatric Brain Cancers At Plus Therapeutics, we’re advancing the future of cancer care with REYOBIQ™ (rhenium-186 Re obisbemeda), our lead targeted...

read more

Introducing REYOBIQ™

Introducing REYOBIQ™: The FDA-Accepted Proprietary Name for Plus Therapeutics’ Lead Drug Candidate Big News from Plus Therapeutics! The U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name REYOBIQ™ (rhenium Re186 obisbemeda) for our...

read more

#RareDiseaseDay2025

Shining a Light on Rare Diseases: Raising Awareness Together At Plus Therapeutics, we are committed to advancing research and innovative treatments for rare and challenging diseases. Today, on Rare Disease Day, we stand with patients, caregivers, and advocates...

read more

Welcome Michael Rosol, PhD!

Plus Therapeutics Appoints Michael Rosol, Ph.D., as Chief Development Officer We are excited to announce the appointment of Michael Rosol, Ph.D., as Chief Development Officer at Plus Therapeutics. In this role, Dr. Rosol will oversee the company’s clinical,...

read more